DDIT3 and lymphoma: Selinexor significantly increased CD20 expression on the surface of B-NHL cells, inhibited the proliferation of double-hit (Bcl-2 and C-Myc mutation-positive) lymphoma cell lines, and exerted a remarkable synergistic effect when combined with CHOP [29].